Society diversity

Illumina Genomics Forum to Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics

Posted 08/25/22

Proposed by Illuminated

Originally posted on Illumina News Center

SAN DIEGO, Aug. 25, 2022 /CSRwire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced it will feature Dr. Karen Knudsen , CEO of the American Cancer Society, at his inaugural Illumina Genomics Forum (IGF) on October 1. Dr. Knudsen will participate in an onstage conversation with Dr. Phil Febbo, Illumina Medical Director, about the landscape of cancer treatment and research, including that fact to support cancer prevention, detection and treatment .

During the discussion, Dr. Knudsen will share her experience of the growing and revolutionary use of clinical genomics in oncology, including the gaps that still need to be filled. She will also share her thoughts on the essential role of the public and private sectors in promoting the use of clinical genomics in oncology.

“Dr. Knudsen and the American Cancer Society are incredible advocates for cancer patients and their loved ones,” said Dr. Phil Febbo. “As genomics continues to revolutionize the way we detect, diagnose and treat cancer, it will be fabulous to discuss with Dr. Knudsen how cancer genomics can best improve patient outcomes.”

Illumina previously announced that former US President Barack Obama will headline the inaugural forum during a fireside chat on the evening of Wednesday, September 28. Twelve years after the Affordable Care Act was passed, Obama will discuss the continued need for equity, accessibility, and smarter health care to improve the human condition. Additionally, on September 30, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health.

Other key IGF themes include:

  • How Genomics Technology is Driving More Informed, Proactive and Personalized Patient Diagnosis and Treatment in Clinics
  • Ways whole genome sequencing is revolutionizing patient care
  • The Role of Genomics in Supporting the Quadruple Aim of Health Care to Improve Population Health, Reduce Costs, Improve Patient Experience, and Improve Provider Satisfaction

The IGF will take place in San Diego from September 28 to October 1. For more information and to register for the conference, go to illuminationnomicsforum.com.

About Illumina

Illumina improves human health by unlocking the power of the genome. Our focus on innovation has enabled us to become a global leader in DNA sequencing and chip-based technologies, serving customers in the research, clinical and application markets. Our products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and join us on Twitter, Facebook, LinkedIn, instagramand Youtube.

Investors:
Salli Schwartz
858.291.6421
IR@illumina.com

Media:
Adi Raval
US: 202.629.8172
PR@illumina.com

SOURCEIllumina, Inc.

Illumina Logo

Illuminated

Illuminated

Illumina improves human health by unlocking the power of the genome. Our focus on innovation has enabled us to become the world leader in DNA sequencing and chip-based technologies, serving customers in the research, clinical and application markets. Our products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments.

More Illuminated